Intensifying Insulin Therapy from Basal Insulin to Biphasic Insulin Aspart (BIAsp 30) Improves Glucose Control and Treatment Satisfaction in Patients with Type 2 Diabetes: South Korea Subgroup of IMPROVE™ Study

被引：0
|
作者：
Kim, Chong Hwa
Jeong, Su Jin
Mok, Ji Oh
Ryu, Ohk Hyun
Lee, Kiyoung
Jeong, In Kyung
Lee, Byung Wan
Kim, Hyun Jin
Lee, Sora
Kim, Sun Woo
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A566 / A566
页数：1
相关论文
共 50 条
  • [21] Insulin Degludec/Insulin Aspart (IDegAsp) Twice Daily (BID) vs. Biphasic Insulin Aspart 30 (BIAsp 30) BID-A Randomized Trial in Chinese Patients with Type 2 Diabetes
    Yang, Wenying
    Ma, Jianhua
    Hong, Tianpei
    Liu, Ming
    Miao, Heng
    Peng, Yongde
    Wang, Changjiang
    Xu, Xiangjin
    Yang, Tao
    Nielsen, Anne Moeller
    Pan, Lili
    Liu, Weihong
    Zhao Weigang
    DIABETES, 2018, 67
  • [22] Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: Results from the ASEAN subgroup of the A1chieve study
    Hussein, Zanariah
    Lim-Abrahan, Mary Anne
    Jain, Anand B.
    Goh, Su Yen
    Soewondo, Pradana
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2013, 100 : S24 - S29
  • [23] Patients with type 2 diabetes mellitus poorly controlled on biphasic human insulin alone show improved glucose control with biphasic insulin aspart 30
    Shestakova, Marina V.
    Lebedev, Nikolay
    Bech, Ole M.
    DIABETES, 2008, 57 : A560 - A560
  • [24] Improved glycemic control with NovoMix® 30 (BIAsp 30) in insulin-naive patients with type 2 diabetes:: Subgroup analysis from the IMPROVE™ study
    Gumprecht, Janusz
    Hansen, Jes B.
    Borzi, Vito
    DIABETES, 2008, 57 : A577 - A577
  • [25] Intensifying Insulin Therapy with Insulin Analog Premixes: Transitioning from Basal Insulin in Type 2 Diabetes
    Shanik, Michael H.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (06) : 533 - 539
  • [26] Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study
    Valensi, P.
    Benroubi, M.
    Borzi, V.
    Gumprecht, J.
    Kawamori, R.
    Shaban, J.
    Shah, S.
    Shestakova, M.
    Wenying, Y.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (03) : 522 - 531
  • [27] Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: results from a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 in routine clinical practice
    Shestakova, M. V.
    Akil, Ballan
    DIABETES MELLITUS, 2010, 13 (01): : 92 - 100
  • [28] Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study
    Khutsoane, D.
    Sharma, S. K.
    Almustafa, M.
    Jang, H. C.
    Azar, S. T.
    Danciulescu, R.
    Shestakova, M.
    Ayad, N. M. A.
    Guler, S.
    Bech, O. M.
    DIABETES OBESITY & METABOLISM, 2008, 10 (03): : 212 - 222
  • [29] IMPROVE study: initiation of biphasic insulin BIAsp30 in type 2 diabetics
    Valensi, Paul
    METABOLISMES HORMONES DIABETES ET NUTRITION, 2008, 12 (06): : 222 - 223
  • [30] IMPROVE (TM) observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus
    Kawamori, Ryuzo
    Valensi, Paul
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (04) : 507 - 516
12345